Core Insights - RxSight, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following a significant drop in stock price and revised revenue guidance [2][3]. Financial Performance - For Q2 2025, RxSight reported expected revenue of $33.6 million, which is a decrease of 4% year-over-year and a decrease of 11% compared to Q1 2025 [3]. - The company revised its 2025 revenue guidance, lowering the midpoint from $167.5 million to $125 million [3]. Market Reaction - Following the announcements regarding financial results and guidance, RxSight's stock price fell by $4.84 per share, or 37.84%, closing at $7.95 per share on July 9, 2025 [3]. Analyst Actions - Wells Fargo and BTIG downgraded RxSight's stock, citing "structural issues" and a challenging competitive environment [3].